8 assets in Anogenital Human Papillomavirus Infection

Therapeutic assets addressing Anogenital Human Papillomavirus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
9-valent human papillomavirus recombinant vaccine Anogenital Human Papillomavirus Infection	Xiamen University	P3	B (60)
Tsc-200-A0201 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-201-B0702 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-202-A0201 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-203-A0201 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0101 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-A0201 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)
Tsc-204-C0702 Anogenital Human Papillomavirus Infection	TScan Therapeutics, Inc.	P1	CC (43)